Exploring the reliability and validity of clinically-relevant outcome measures for chemotherapy-induced peripheral neuropathy.
Adult
Aged
Female
Humans
Male
Middle Aged
Antineoplastic Agents
/ adverse effects
Cancer Survivors
Neoplasms
/ drug therapy
Outcome Assessment, Health Care
/ methods
Peripheral Nervous System Diseases
/ chemically induced
Postural Balance
/ drug effects
Quality of Life
Reproducibility of Results
Surveys and Questionnaires
Chemotherapy-Induced peripheral neuropathy
Psychometrics, Reliability, Validity
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
01
02
2024
accepted:
12
09
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
19
9
2024
Statut:
epublish
Résumé
To explore the reliability and validity of clinically-relevant outcome measures for balance (i.e., The Short Physical Performance Battery [SPPB] - Balance Subscale) and sensation (i.e., monofilament threshold testing) for use in clinical trials of chemotherapy-induced peripheral neuropathy (CIPN). Adult, post-treatment cancer survivors (N = 142) who had reported ≥ 4/10 CIPN symptom severity following neurotoxic chemotherapy were recruited from six National Cancer Institute Community Oncology Research Program (NCORP) sites associated with the University of Rochester Cancer Center NCORP Research Base. Participants completed the monofilament threshold test at the screening and baseline time points (i.e., one week apart), while the Quality of Life Questionnaire-CIPN20, Treatment-Induced Neuropathy Assessment Scale, and SPPB - Balance Subscale were completed at baseline. Test-retest reliability of the monofilament threshold testing scores was assessed using the Intraclass Correlation Coefficient (ICC). The convergent validity among monofilament threshold testing, SPPB - Balance Subscale, and CIPN patient-reported outcome (PRO) scores at baseline was assessed using Spearman's correlation. Ceiling effects were observed for SPPB-Balance Subscale scores as 113 (79.6%) respondents reported the highest score. Agreement between the screening and baseline monofilament threshold testing scores was moderate (ICC = 0.65). Monofilament threshold testing (r Monofilament threshold testing demonstrated moderate test-retest reliability, but low convergent validity with CIPN PROs, while the SPPB - Balance Subscale demonstrated low convergent validity with CIPN PROs and ceiling effects (i.e., highest possible score) among post-treatment cancer survivors with CIPN. Future research is needed to identify promising measures of balance and sensation loss for use in clinical trials that complement CIPN PROs to aid in the identification of clinically relevant treatments for CIPN. NCT04367490 [April 29, 2020].
Identifiants
pubmed: 39297964
doi: 10.1007/s00520-024-08878-5
pii: 10.1007/s00520-024-08878-5
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
675Subventions
Organisme : National Institute for Neurologic Disorders and Stroke
ID : K24NS126861
Organisme : NCI NIH HHS
ID : R21CA235389
Pays : United States
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Gewandter JS, Fan L, Magnuson A et al (2013) Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer 21:2059–2066. https://doi.org/10.1007/s00520-013-1766-y
doi: 10.1007/s00520-013-1766-y
pubmed: 23446880
pmcid: 3669650
Monfort SM, Pan X, Patrick R et al (2017) Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Res Treat 164:69–77. https://doi.org/10.1007/s10549-017-4230-8
doi: 10.1007/s10549-017-4230-8
pubmed: 28374323
pmcid: 5510549
Kneis S, Wehrle A, Freyler K et al (2016) Balance impairments and neuromuscular changes in breast cancer patients with chemotherapy-induced peripheral neuropathy. Clin Neurophysiol 127:1481–1490. https://doi.org/10.1016/J.CLINPH.2015.07.022
doi: 10.1016/J.CLINPH.2015.07.022
pubmed: 26350407
Tofthagen CS, Cheville AL, Loprinzi CL (2020) The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy. Curr Oncol Rep 225(22):1–6. https://doi.org/10.1007/S11912-020-00903-0
doi: 10.1007/S11912-020-00903-0
Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367. https://doi.org/10.1001/jama.2013.2813
doi: 10.1001/jama.2013.2813
pubmed: 23549581
pmcid: 3912515
Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 38(28):3325–3348. https://doi.org/10.1200/JCO.20.01399
doi: 10.1200/JCO.20.01399
pubmed: 32663120
Gewandter JS, Freeman R, Kitt RA et al (2017) Chemotherapy-induced peripheral neuropathy clinical trials: Review and recommendations. Neurology 89:859–869. https://doi.org/10.1212/WNL.0000000000004272
doi: 10.1212/WNL.0000000000004272
pubmed: 28747442
pmcid: 10681068
Park SB, Tamburin S, Schenone A et al (2022) Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion. Expert Rev Neurother 22:65–76. https://doi.org/10.1080/14737175.2022.2018300
doi: 10.1080/14737175.2022.2018300
pubmed: 34894974
pmcid: 8963967
Guralnik JM, Simonsick EM, Ferrucci L et al (1994) A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 49(2):M85-94. https://doi.org/10.1093/GERONJ/49.2.M85
doi: 10.1093/GERONJ/49.2.M85
pubmed: 8126356
Gewandter JS, Dale W, Magnuson A et al (2015) Associations between a patient-reported outcome (PRO) measure of sarcopenia and falls, functional status, and physical performance in older patients with cancer. J Geriatr Oncol 6:433–441. https://doi.org/10.1016/J.JGO.2015.07.007
doi: 10.1016/J.JGO.2015.07.007
pubmed: 26365897
pmcid: 4661107
Loh KP, Pandya C, Zittel J et al (2017) Associations of sleep disturbance with physical function and cognition in older adults with cancer. Support Care Cancer 25:3161–3169. https://doi.org/10.1007/S00520-017-3724-6
doi: 10.1007/S00520-017-3724-6
pubmed: 28455547
pmcid: 5660663
Lee CE, Warden SJ, Szuck B, Lau YKJ (2016) A Preliminary Study on the Efficacy of a Community-Based Physical Activity Intervention on Physical Function-Related Risk Factors for Falls Among Breast Cancer Survivors. Am J Phys Med Rehabil 95:561–570. https://doi.org/10.1097/PHM.0000000000000440
doi: 10.1097/PHM.0000000000000440
pubmed: 26829081
pmcid: 4949097
Gewandter JS, Chaudari J, Ibegbu C et al (2019) Wireless transcutaneous electrical nerve stimulation device for chemotherapy-induced peripheral neuropathy: an open-label feasibility study. Support Care Cancer 27:1765–1774. https://doi.org/10.1007/S00520-018-4424-6
doi: 10.1007/S00520-018-4424-6
pubmed: 30151681
Gewandter JS, Culakova E, Davis JN et al (2024) Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Proof-of-Concept Randomized Clinical Trial. J Pain 25(5):104431. https://doi.org/10.1016/J.JPAIN.2023.11.014
doi: 10.1016/J.JPAIN.2023.11.014
pubmed: 37993030
Postma TJ, Aaronson NK, Heimans JJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41:1135–1139. https://doi.org/10.1016/j.ejca.2005.02.012
doi: 10.1016/j.ejca.2005.02.012
pubmed: 15911236
Dorsey SG, Kleckner IR, Barton D et al (2019) The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. JNCI J Natl Cancer Inst. https://doi.org/10.1093/jnci/djz011
doi: 10.1093/jnci/djz011
pubmed: 30715378
Mendoza TR, Wang XS, Williams LA et al (2015) Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. J Pain 16:1032–1043. https://doi.org/10.1016/J.JPAIN.2015.07.002
doi: 10.1016/J.JPAIN.2015.07.002
pubmed: 26210041
pmcid: 4592444
Williams LA, Garcia-Gonzalez A, Mendoza TR et al (2019) Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS). Support Care Cancer 27:1021–1028. https://doi.org/10.1007/S00520-018-4391-Y/TABLES/3
doi: 10.1007/S00520-018-4391-Y/TABLES/3
pubmed: 30094731
Mendoza TR, Williams LA, Shi Q et al (2020) The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment. J Patient Rep Outcomes 41(4):1–9. https://doi.org/10.1186/S41687-020-0180-8
doi: 10.1186/S41687-020-0180-8
Dyck PJ, Herrmann DN, Staff NP, Dyck PJB (2013) Assessing decreased sensation and increased sensory phenomena in diabetic polyneuropathies. Diabetes 62:3677–3686. https://doi.org/10.2337/DB13-0352
doi: 10.2337/DB13-0352
pubmed: 24158999
pmcid: 3806590
Koo TK, Li MY (2016) A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med 15:155–163. https://doi.org/10.1016/j.jcm.2016.02.012
doi: 10.1016/j.jcm.2016.02.012
pubmed: 27330520
pmcid: 4913118
Terwee CB, Bot SDM, de Boer MR et al (2007) Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 60:34–42. https://doi.org/10.1016/j.jclinepi.2006.03.012
doi: 10.1016/j.jclinepi.2006.03.012
pubmed: 17161752
Gewandter JS, Brell J, Cavaletti G et al (2018) Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology 91:403–413. https://doi.org/10.1212/WNL.0000000000006083
doi: 10.1212/WNL.0000000000006083
pubmed: 30054438
pmcid: 6133627
McNeish BL, Dittus K, Mossburg J et al (2023) Executive function is associated with balance and falls in older cancer survivors treated with chemotherapy: A cross-sectional study. J Geriatr Oncol 14(8):101637. https://doi.org/10.1016/J.JGO.2023.101637
doi: 10.1016/J.JGO.2023.101637
pubmed: 37776612
Menant JC, Goldstein D, Au K et al (2021) Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy. Gait Posture 89:178–185. https://doi.org/10.1016/J.GAITPOST.2021.07.010
doi: 10.1016/J.GAITPOST.2021.07.010
pubmed: 34320441
Saito T, Makiura D, Inoue J et al (2020) Comparison between quantitative and subjective assessments of chemotherapy-induced peripheral neuropathy in cancer patients: A prospective cohort study. Phys Ther Res 23:166–171. https://doi.org/10.1298/PTR.E10027
doi: 10.1298/PTR.E10027
pubmed: 33489655
pmcid: 7814216
Cheng HL, Lopez V, Lam SC et al (2020) Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. Health Qual Life Outcomes 18:246. https://doi.org/10.1186/s12955-020-01493-y
doi: 10.1186/s12955-020-01493-y
pubmed: 32703223
pmcid: 7376939
Stoller S, Capozza S, Alberti P et al (2023) Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN). Support Care Cancer 31:293. https://doi.org/10.1007/S00520-023-07734-2
doi: 10.1007/S00520-023-07734-2
pubmed: 37086308
Knoerl R, Wallar J, Fox E et al (2023) Exploring Clinicians’ Perspectives of Barriers to Chemotherapy-Induced Peripheral Neuropathy Assessment and Management in Oncology Practice: A Qualitative Analysis of Semi-structured Interviews. Cancer Nurs 46:103–110. https://doi.org/10.1097/NCC.0000000000001082
doi: 10.1097/NCC.0000000000001082
pubmed: 35283473
McCrary JM, Goldstein D, Wyld D et al (2019) Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. J Cancer Surviv. https://doi.org/10.1007/s11764-019-00769-7
doi: 10.1007/s11764-019-00769-7
pubmed: 31172429
Knoerl R, Gilchrist L, Kanzawa-Lee GA et al (2020) Proactive Rehabilitation for Chemotherapy-Induced Peripheral Neuropathy. Semin Oncol Nurs 36(1):150983. https://doi.org/10.1016/J.SONCN.2019.150983
doi: 10.1016/J.SONCN.2019.150983
pubmed: 31959510